Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Status:
Recruiting
Trial end date:
2023-04-16
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well ramucirumab and paclitaxel or the FOLFIRI regimen
(leucovorin calcium, fluorouracil, and irinotecan hydrochloride) work in treating patients
with small bowel cancers that have spread extensively to other anatomic sites (advanced) or
are no longer responding to treatment (refractory). Ramucirumab is a monoclonal antibody that
attaches to and inhibits a molecule called VEGFR-2. This may restrain new blood vessel
formation therefore reducing nutrient supply to tumor which may interfere with tumor cell
growth and expansion. Drugs used in chemotherapy, such as paclitaxel, leucovorin calcium,
fluorouracil, and irinotecan hydrochloride work in different ways to stop the growth of tumor
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving Ramucirumab plus paclitaxel or FOLFIRI, may be helpful in treating advanced
or refractory small bowel cancers and may help patients live longer.